Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

How does cosentyx's success rate compare to humira?

See the DrugPatentWatch profile for cosentyx

What do the reported “success rates” mean for Cosentyx vs. Humira?

“Success rate” can mean different endpoints depending on the disease (psoriasis, psoriatic arthritis, ankylosing spondylitis) and the study design. To compare Cosentyx and Humira accurately, you need the specific indication and the outcome being called a success rate (for example, skin clearance rates in psoriasis, or response rates in joint disease) from the same type of trial.

How do you compare them if you mean psoriasis skin clearance?

In plaque psoriasis studies, drug performance is often reported as the percentage of patients who achieve a high level of skin clearance at a set time point (commonly measured with PASI-75 or PASI-90). Without the specific endpoint and trial timeframe you mean, a direct Cosentyx-versus-Humira “success rate” comparison can be misleading.

How do you compare them if you mean psoriatic arthritis or ankylosing spondylitis improvement?

For psoriatic arthritis and ankylosing spondylitis, “success” is typically measured with composite clinical response scores at specific weeks (for example, measures of joint symptoms, function, and inflammation). The Cosentyx and Humira results aren’t interchangeable unless you compare the same disease, the same response metric, and the same follow-up duration.

Why head-to-head comparison matters

Cosentyx and Humira are studied across multiple indications and trial programs. Even when endpoints sound similar, differences in trial eligibility, background meds, scoring methods, and follow-up times can change the observed “success rate.” A fair comparison usually comes from either head-to-head trials (rare for these biologics) or carefully matched indirect comparisons that use the same outcome definitions.

Tell me which “success rate” you want, and I can compare it

If you share:
1) the condition (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis), and
2) what endpoint you mean by “success rate” (e.g., PASI-75, PASI-90, ACR/NRS response, etc.), and
3) the time point (e.g., week 12, week 16),

…I can give a precise side-by-side comparison for Cosentyx versus Humira using the corresponding study results.



Other Questions About Cosentyx :

Should cosentyx be stopped before every vaccine? How is cosentyx dosage adjusted for obesity? How does the effectiveness of cosentyx vary among elderly patients? How has cosentyx impacted your life? Are there any recommended adjustments to cosentyx dosage for arthritis? What is cosentyx? How does cosentyx s effectiveness stack up against competitors?